90 results on '"Magrini F."'
Search Results
2. Distributed field plate effects in split-gate trench MOSFETs
3. Shear‐Velocity Structure and Dynamics Beneath the Sicily Channel and Surrounding Regions of the Central Mediterranean Inferred From Seismic Surface Waves
4. Haemodynamic development
5. Intervention of Single Risk Factor: Hypertension
6. Target organ damage in hypertensive patients: correlation between retinal arteriovenular ratio and left ventricular geometric patterns
7. THU0096 Mavrilimumab in rheumatoid arthritis: Results of a phase 2 double-blind, placebo controlled study
8. FRI0182 Pharmacokinetics and immunogenicity of mavrilimumab administered subcutaneously in subjects with rheumatoid arthritis
9. AB0576 Evaluation of surfactant protein-D and KL-6 as potential pulmonary safety biomarkers during mavrilimumab treatment
10. SAT0483 Incidence density of serious and opportunistic infections and TB reactivation after biologic treatment in patients with rheumatoid arthritis – a review of the literature
11. Pathophysiology and clinical studies in CKD 1-5
12. Limited Hypotensive Effect of Sildenafil in a High-Risk Population: A Preliminary Report
13. OFFICE BLOOD PRESSURE MONITORING (OBPM): A POSSIBLE NEW TOOL FOR EVALUATING BLOOD PRESSURE IN CHILDREN AND ADOLESCENTS
14. FOOD INFLUENCE ON BLOOD PRESSURE: OBSERVATION FROM THE SIXTH WORLD HYPERTENSION DAY
15. COMPARISON OF BLOOD PRESSURE CHANGES IN THE STANDING POSITION AFTER SUPINE-VERSUS SEATED- REST IN ESSENTIAL HYPERTENSIVES
16. “SMS THERAPY”: A NEW APPROACH TO INCREASING COMPLIANCE TO ANTIHYPERTENSIVE TREATMENT
17. LEFT VENTRICULAR GEOMETRIC PATTERN AND ABPM PROFILE IN THE ELDERLY
18. BLOOD PRESSURE MONITORING AND LVM IN CENTENARIANS
19. OPPOSITE CHANGES OF PLASMA RENIN ACTIVITY AND ALDOSTERONE INDUCED BY SUNITINIB TREATMENT IN NEOPLASTIC PATIENTS
20. Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor- , in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study
21. LOSARTAN (L) BUT NOT ATENOLOL (A) REDUCES AN INDEX OF CARDIAC FIBROSIS IN HYPERTENSIVE PATIENTS WITH LEFT VENTRICULAR HYPERTROPHY (LVH): A LIFE SUBSTUDY: PP.22.352
22. AGE-DEPENDENT DIFFERENCES IN OFFICE (OBP) VS AMBULATORY BLOOD PRESSURE MONITORING (ABPM) IN HYPERTENSIVE CHILDREN AND ADOLESCENTS: 8C.03
23. INCIDENCE OF ORTHOSTATIC HYPOTENSION IN TREATED ESSENTIAL HYPERTENSIVES: PP.15.76
24. 7.1 Left Ventricular Strain in Subjects Affected from Arterial Hypertension
25. Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti–tumor necrosis factor therapy
26. Données de tolérance à long terme après traitement et retraitement par RTX dans la polyarthrite rhumatoïde
27. Réponse clinique après un premier traitement par rituximab: relation avec les taux d'autoanticorps (FR, anti-CCP) à l'état basal
28. Direct visualization of neo-vessel formation following peripheral injection of bone marrow derived CD34+ cells in experimental myocardial damage
29. How Long Shall the Patient Rest Before Clinic Blood Pressure Measurement?
30. Isolated ambulatory hypertension and changes in target organ damage in treated hypertensive patients
31. Prevalence and correlates of advanced retinopathy in a large selected hypertensive population. The Evaluation of Target Organ Damage in Hypertension (ETODH) study
32. What is the accuracy of clinic blood pressure measurement?
33. High-Altitude trekking in the Himalayas increases the activity of circulating endothelial cells
34. Evaluation of cardiac structure by echoreflectivity analysis in acromegaly: effects of treatment
35. CARDIOVASCULAR RISK STRATIFICATION ACCORDING TO THE 2003 ESH-ESC GUIDELINES IN PATIENTS WITH ESSENTIAL HYPERTENSION
36. INCREASED MYOCARDIAL REFLECTIVITY IN HYPERTENSIVE PATIENTS
37. CHANGES IN CAROTID WALL COMPOSITION FOLLOWING ANTIHYPERTENSIVE TREATMENT
38. WHAT IS THE ACCURACY OF CLINIC BLOOD PRESSURE MEASUREMENT? A HEMODYNAMIC STUDY
39. METABOLIC SYNDROME AND TARGET ORGAN DAMAGE IN UNTREATED ESSENTIAL HYPERTENSIVES
40. RETINAL MICROVASCULAR CHANGES AND TARGET ORGAN DAMAGE IN UNTREATED ESSENTIAL HYPERTENSIVES
41. DIFFERENT EFFECTS OF ANTIHYPERTENSIVE THERAPIES BASED ON LOSARTAN OR ATENOLOL ON ULTRASOUND AND BIOCHEMICAL MARKERS OF MYOCARDIAL FIBROSIS
42. Home blood pressure measurement and its relationship with blood pressure control in a large selected hypertensive population
43. REPRODUCIBILITY OF NOCTURNAL BLOOD PRESSURE FALL IN EARLY PHASES OF UNTREATED ESSENTIAL HYPERTENSION
44. PREVALENCE OF BLOOD PRESSURE SELF-MEASUREMENT AND ITS RELATIONSHIP WITH BLOOD PRESSURE CONTROL IN A LARGE SELECTED HYPERTENSIVE POPULATION. A PROSPECTIVE OBSERVATIONAL STUDY
45. CARDIOVASCULAR RISK STRATIFICATION ACCORDING TO THE 2003 ESH-ESC GUIDELINES IN UNCOMPLICATED PATIENTS WITH ESSENTIAL HYPERTENSION
46. Reproducibility of nocturnal blood pressure fall in early phases of untreated essential hypertension: a prospective observational study
47. Reduced nocturnal fall in blood pressure, assessed by two ambulatory blood pressure monitorings and cardiac alterations in early phases of untreated essential hypertension
48. Change in cardiovascular risk profile by echocardiography in medium-risk elderly hypertensives
49. Left ventricular concentric remodelling and extracardiac target organ damage in essential hypertension
50. A Comparison of Blood Pressure Control in a Hypertension Hospital Clinic Between 1997 and 2000
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.